Abbott Shaves U.S. Pharma Costs With Restructuring
This article was originally published in The Pink Sheet Daily
Executive Summary
Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.
You may also be interested in...
The Abbott Split Up: Who Wins?
After implementing a major workforce reduction in January, Abbott Laboratories re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company.
Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.
Abbott To Split Into Two Publicly Traded Companies Over Next 12 Months
Analysts see break-up as an effort to unlock value for proprietary pharmaceuticals unit, where expectations of slowing Humira sales may have left the company undervalued.